Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2019-A00327-50 | Other Identifier | ID-RCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| French Association for Research on Multiple Sclerosis | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Urinary disorders (UD) are common in Multiple Sclerosis (MS) and can necessitate using Intermittent Self Catheterisation (ISC). It is well experienced by patients, has little impact on daily life and improves quality of life. However, studies are lacking on long-term adherence to this treatment as well as on discontinuation factors. Our main objective is to prospectively assessed factors associated with ISC discontinuation 2 years after having introduced this technique.
Urinary disorders (UD) are common in Multiple Sclerosis (MS). About 65% of patients suffering from moderate to severe troubles. In case of voiding dysfunction, the reference treatment is based on intermittent self catheterisation (ISC). UD in spinal cord injury (SCI) patients have been widely studied. They are very common, and are life-threatening in the absence of appropriate care. Management of neurological UD (as those occurring in MS) are well defined. ISC is the gold standard of bladder emptying method in this pathological context, and has been the subject of numerous studies. In SCI, the ISC discontinuation rate varies from 52 to 80% according to the published studies, the main factors of continuation being the autonomy to perform the technique, and the continence rate. However, the results are variable. In case of MS, the studies are lacking, the results concerning the discontinuation rate and factors associated with discontinuation are poor. Our main objective within the French speaking neurology study group (GENULF), is to prospectively assessed factors associated with ISC discontinuation 2 years after having introduced this technique.
This predictive study will be multicenter, observational, analytical, and prospective and will not modify current clinical practice.
We will record clinical and urinary data at each visit (inclusion, 6 weeks, 6 months, 12 months, and 24 months). We will note also if the patient practice ISC as prescribed in order to identify discontinuation of the ISC.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| patient with multiple sclerosis | At each visit, inclusion, 6 weeks, 6 months, 12 months, and 24 months, the clinical and urinary data will be recorded and the ISC frequency , ISC discontinuation and adherence scale will be evaluated |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| data record | Other | At each protocol's visit, clinical and urinary data will be recorded and the answers of the questionnaires will be also reported |
|
| Measure | Description | Time Frame |
|---|---|---|
| intermittent self catheterisation discontinuation at 2 years after the start of learning. | intermittent self catheterisation frequency and the adherence scorage will be evaluated for each patient. | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| intermittent self catheterisation discontinuation at 6 weeks, after the start of learning. | intermittent self catheterisation frequency will be evaluated for each patient. | 6 WEEKS |
| intermittent self catheterisation discontinuation 6 months after the start of learning. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Multiple Sclerosis Patients requiring Intermittent Self Catheterisation
Not provided
| Name | Affiliation | Role |
|---|---|---|
| castel lacanal EVELYNE | University Hospital, Toulouse | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UHToulouse | Toulouse | 31059 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D057286 | Electronic Health Records |
| D011795 | Surveys and Questionnaires |
| ID | Term |
|---|---|
| D016347 | Medical Records Systems, Computerized |
| D008499 | Medical Records |
| D011996 | Records |
| D003625 | Data Collection |
Not provided
Not provided
Not provided
Not provided
Not provided
|
intermittent self catheterisation frequency will be evaluated for each patient. |
| 6 months |
| intermittent self catheterisation discontinuation at 1 year after the start of learning. | intermittent self catheterisation frequency will be evaluated for each patient. | 1 year |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D004812 |
| Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D009934 | Organization and Administration |
| D006298 | Health Services Administration |
| D017531 | Health Care Evaluation Mechanisms |
| D011787 | Quality of Health Care |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |